Biomica Advances to Pre-Clinical Studies in its IBD Program
Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) and (TASE: EVGN), announces the initiation of pre-clinical studies for BMC321 & BMC322, two rationally-designed microbial consortia aimed […]